Vitamins such as anticancer shield

Unlike carbohydrates, fats and proteins, vitamins are not an energy source, but also serve as chemical models for enzymes related to metabolic function, cell production, tissue repair and other vital processes.

Vitamin C, and precursor of vitamin A as beta-carotene, are antioxidants, and hence are considered as protectors of the oxidation of cells, and thus of degenerative diseases such as cancer.

Protein HLJ1 slowing the progression lung cancer

An investigation identified a protein that may curb lung cancer. HLJ1 protein is involved in slowing the progression of lung cancer, the researchers said.
Scientists at the National Taiwan University (China) have concluded that a protein called HLJ1 could function as tumor suppressor in non-small cell lung cancer.

The study, published in the Journal of the National Cancer Institute was based on increasing or blocking HLJ1 expression in lung carcinoma cells, and gene expression observed in tumors and adjacent tissue cells in 71 patients with cancer NSCLC.

Melanoma vaccine

Hundred percent development argentinoUna melanoma vaccine ready for final test Will be tested in 108 patients with skin cancer, would be available in 3 or 4 years.

Argentine researchers have developed a vaccine to treat melanoma, the most common form of cancer in people aged between 15 and 44 years will begin in the coming months with phase studies in patients prior to approval by authorities local regulatory. If you pass this last test, called Vaccimel vaccine could be available in 3 to 4 years. "After three years of receiving the vaccine, 70% of patients in advanced stages of melanoma who participated in clinical studies so far remained free of disease," said Dr. Marcela Barrio, CONICET researcher involved in the development of Vaccimel, during a press conference held in Expo-Medical.

Treatment of neutrophils by Antonio Bru

In 1993, Doctor in Physics Antonio Bru works in the CIEMAT, the Ministry of Education and Science ...

Enjoy a contract under the project, and his work focuses on hydration fronts in heterogeneous materials, forming part of a containment of high level radioactive waste. In his paper studies the phenomena of molecular diffusion of a medium in another, and building on similarities that sometimes have physical and biological phenomena of very different nature, almost like a mathematical curiosity, became interested in the dynamics of tumor growth. He realizes that in its opinion:

Out of context

Sometimes silence is not one or two pieces of evidence or not to read in Polish ... .. attitude just a little reluctant ... ...

Olympics a little bit of contempt which is considered an upstart and a little bit of pride and corporatism to admit that unfortunately the much-worn "scientific method" has not been responsible or the 10% of the great discoveries of mankind and also Unfortunately (for patients) 1000 Oncologists continue to fail than 100,000 times a year without the 100 failures per capita serve for a high pedestal of wounded pride and put the hard work to provide all necessary support to clarify the real limits and the real possibilities of something that sometimes starts with one or two pieces of evidence that seem to contradict the paradigm "official" and end in late Nobel Prize ....

SUTENT/SU11248 improves survival in Gleevec-resistant GIST

ORLANDO, Florida, May 16 / PRNewswire / - There have been four types of tumors at ASCO

The investigational new drug from Pfizer Inc, SUTENT/SU11248 (sunitinib malate) has doubled the survival rate ...

and reduced the growth and spread of tumors in a Phase III study in patients with gastrointestinal stromal tumors resistant to Gleevec (GIST). The promising results achieved in Phase II analysis were also observed in other tumor types, including metastatic carcinoma of the renal cell carcinoma (mRCC), metastatic breast cancer and neuroendocrine tumors, according to new data presented this week at the annual meeting American Society of Clinical Oncology (ASCO).